MAIA Biotechnology Opens Third U.S. Site for Phase 2 NSCLC Trial After >2-Year Survival Signals
MAIA•MAIA Biotechnology activated the third U.S. clinical site at Winship Cancer Institute for its Phase 2 THIO-101 expansion trial studying telomere-targeting agent ateganosine in third-line non-small cell lung cancer. Parts A and B showed some patients with survival exceeding two years, prompting broader U.S. enrollment.
1. Phase 2 Expansion Site Activation
MAIA Biotechnology has activated Winship Cancer Institute of Emory University as the third U.S. site in its Phase 2 THIO-101 trial, enrolling patients with third-line non-small cell lung cancer. Winship is Georgia’s only NCI-designated Comprehensive Cancer Center with a leading thoracic oncology research program.
2. Trial Design and Objectives
THIO-101 is an open-label, dose-finding study evaluating low-dose ateganosine followed by cemiplimab in patients resistant to checkpoint inhibitors and chemotherapy. The primary objectives are to assess safety, tolerability and overall response rate in heavily pretreated advanced NSCLC patients.
3. Early Efficacy Data
Parts A and B of the trial demonstrated strong early efficacy signals, with some patients achieving survival beyond two years. These durable responses have driven the expansion to additional U.S. clinical sites to further assess ateganosine’s potential benefit.
